The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Smirnova O.V.

Oncology Clinical Dispensary One, Moscow Healthcare Department;
Department of Oncology and Radiation Therapy, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Borisov V.I.

Oncology Clinical Dispensary One, Moscow Healthcare Department

Immunotherapy in the drug treatment of patients with triple-negative metastatic breast cancer

Authors:

Smirnova O.V., Borisov V.I.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2018;7(6): 60‑66

DOI: 10.17116/onkolog2018706160

Read: 6258 times

Download PDF (RU)
Contact the author
Table of contents

IMMUNOTHERAPY IN THE DRUG TREATMENT OF PATIENTS WITH TRIPLE-NEGATIVE METASTATIC BREAST CANCER
IMMUNOTHERAPY IN THE DRUG TREATMENT OF PATIENTS WITH TRIPLE-NEGATIVE METASTATIC BREAST CANCER

To cite this article:

Smirnova OV, Borisov VI. Immunotherapy in the drug treatment of patients with triple-negative metastatic breast cancer. P.A. Herzen Journal of Oncology. 2018;7(6):60‑66. (In Russ.)
https://doi.org/10.17116/onkolog2018706160

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Anti­gen rece­ptors in the deve­lopment of CAR-T cells for glioblastoma immu­notherapy. P.A. Herzen Journal of Onco­logy. 2024;(6):91-95
Effi­cacy of chemoimmunotargeted therapy in patients with adva­nced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Onco­logy. 2025;(3):63-70
Use of HIFU therapy in combination with mono­chemotherapy in a patient with loca­lly adva­nced adenogenic pancreatic cancer and impaired functional status. P.A. Herzen Journal of Onco­logy. 2025;(3):83-88
Evaluation of the skeletal muscle index in predicting toxic complications of anti­tumor drug therapy in patients with gastric cancer. P.A. Herzen Journal of Onco­logy. 2025;(4):29-36
Claudin-18.2 and gastric cancer: from physiology to carcinogenesis. Russian Journal of Archive of Pathology. 2024;(6):92-99
Possibilities of using bacterial lysa­tes in the treatment and prevention of upper respiratory tract infe­ctious diseases. Russian Rhinology. 2024;(4):314-322
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143
Surgical treatment of intracerebral meta­stases of Ewing sarcoma in children. Case report and review. Burdenko's Journal of Neurosurgery. 2025;(2):92-96
Prognostic value of mole­cular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations. Russian Journal of Archive of Pathology. 2025;(3):88-96
Application of T-cells with chimeric anti­gen rece­ptor in the treatment of refractory autoimmune diseases. Russian Journal of Preventive Medi­cine. 2025;(7):106-110
Abstract:

Breast cancer (BC) is the most commonly diagnosed malignant tumor in women worldwide. With the evolution of molecular biology, immunology, and pharmacogenomics, immunotherapy becomes a new promising area in the treatment of BC. Triple-negative BC (TNBC), unlike other subtypes, is characterized by the absence of drug targets (estrogen receptors, progesterone receptors, and HER-2/neu), by the early development of distant metastases and a poor prognosis, which necessitates a study of the efficiency of immunotherapy as a new area in the treatment of such tumors. At the same time, there are still no uniform standards of treatment for such patients. With the development and introduction of immunotherapy in practice, clinicians may hope that an immunotherapy strategy will become a new priority area in the treatment of patients with TNBC. In 2017, large international conferences, such as ASCO, ESMO, San Antonio Breast Cancer Symposium (SABCS), paid much attention to the treatment for TNBC in general and to the efficiency of immunotherapy in particular.

Keywords:

triple-negative breast cancer
metastases
chemotherapy
immunotherapy
PD-1 inhibitors
PD-L1 inhibitors
tumor infiltrating lymphocytes

Authors:

Smirnova O.V.

Oncology Clinical Dispensary One, Moscow Healthcare Department;
Department of Oncology and Radiation Therapy, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Borisov V.I.

Oncology Clinical Dispensary One, Moscow Healthcare Department

Close metadata

References:

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. 2012. CA Cancer J Clin. 2015;65(2):87-108. https://doi.org/10.3322/caac.21262
  2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752. https://doi.org/10.1038/35021093
  3. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008;34(4):378-390. https://doi.org/10.1016/j.ctrv.2008.01.007
  4. Foukakis T, Fornander T, Lekberg T, Hellborg H, Adolfsson J, Bergh J. Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res Treat. 2011;130(2):553-560. https://doi.org/10.1007/s10549-011-1594-z
  5. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15,Pt1):4429-4434. https://doi.org/10.1158/1078-0432.CCR-06-3045
  6. Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, et al. Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat. 2015;150(3):621-629. https://doi.org/10.1007/s10549-015-3341-3
  7. O’Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014;32(34):3840-3847. https://doi.org/10.1200/JCO.2014.55.2984
  8. Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol. 2012;23(Suppl. 6):vi19-vi22. https://doi.org/10.1093/annonc/mds190
  9. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Syr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11:e0157368. https://doi.org/10.1371/journal.pone.0157368
  10. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravathy AB, Shyr Y, et al. Identification of human triple negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767. https://doi.org/10.1172/JCI45014
  11. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334. https://doi.org/10.1158/1078-0432.CCR-06-1109
  12. Denkert C, Minckwitz VG, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2014;33(9):983-991. https://doi.org/10.1200/JCO.2014.58.1967
  13. Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a metaanalysis. Breast Cancer Res Treat. 2014;148(3):467-476. https://doi.org/10.1007/s10549-014-3185-2
  14. Nanda R. Pembrolizumab shows potential in breast cancer. Cancer Discov. 2015;5(2):100-101. https://doi.org/10.1158/2159-8290.CD-NB2014-184
  15. Tolba MF, Omar HA. Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders. Crit Rev Ocol Hematol. 2018;122(2018):202-207. https://doi.org/10.1016/j.critrevonc.2018.01.005
  16. Apetoh L, Ghiringhelli F, Tesniere A, Obeis M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050-1059. https://doi.org/10.1038/nm1622
  17. Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001;7(10):3025-3030.
  18. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol. 2011;224(3):389-400. https://doi.org/10.1002/path.2866
  19. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-113. https://doi.org/10.1200/JCO.2009.23.7370
  20. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860-867. https://doi.org/10.1200/JCO.2011.41.0902
  21. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959-2966. https://doi.org/10.1200/JCO.2013.55.0491
  22. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361-370. https://doi.org/10.1158/2326-6066.CIR-13-0127
  23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. https://doi.org/10.1016/j.cell.2011.02.013
  24. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. https://doi.org/10.1038/nm730
  25. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381-3385. https://doi.org/10.1158/0008-5472.CAN-05-4303
  26. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007;13(2,Pt2):709s-715s. https://doi.org/10.1158/1078-0432.CCR-06-1868
  27. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13(7):2151-2157. https://doi.org/10.1158/1078-0432.CCR-06-2746
  28. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360-3365. https://doi.org/10.1073/pnas.0611533104
  29. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108(1):19-24. https://doi.org/10.1016/j.acthis.2006.01.003
  30. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11(8):2947-2953. https://doi.org/10.1158/1078-0432.CCR-04-1469
  31. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15(3):971-979. https://doi.org/10.1158/1078-0432.CCR-08-1608
  32. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8(3):190-198. https://doi.org/10.1593/neo.05733
  33. Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25-39. https://doi.org/10.1189/jib.12112621
  34. Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895-904. https://doi.org/10.1084/jem.20160801
  35. Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116-129. https://doi.org/10.1016/j.ejca.2017.08.035
  36. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, et al. Predictive correlates of response to the antiPD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567. https://doi.org/10.1038/nature14011
  37. Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S. Clinical validity and utility of tumor-Infiltrating lymphocytes in routine clinical practice for Breast cancer patients: current and future directions. Front. Oncol. 2017;7:156. https://doi.org/10.3389/fonc.2017.00156
  38. Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E, et al. A different immunologic profile characterizes patients with HER-2 overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Res. 2011;13(6):R117. https://doi.org/10.1186/bcr3060
  39. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571. https://doi.org/10.1038/nature13954
  40. Dirix LY, Takacs I, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167(3):671-686. https://doi.org/10.1007/s10549-017-4537-5
  41. Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228-241. https://doi.org/10.1038/nrclinonc.2015.215
  42. Anders CK, Abramson V, Tan T, Dent R. The evolution of triple-Negative Breast cancer: from biology to novel therapeutics. Am Soc Clin Oncol Educ Book. 2016;35:34-42. https://doi.org/10.14694/EDBK_159135
  43. Dang TO, Ogunniyi A, Barbee MS, Drilon A. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther. 2016;16(1):13-20. https://doi.org/10.1586/14737140.2016.1123626
  44. Adams S, Loi S, Toppmeyer DL. KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1-positive, previous untreated, metastatic triple-negative breast cancer (mTNBC). In: Poster presented at: 2017 San Antonio Breast Cancer Symposium (SABCS). December 7, 2017; San Antonio, TX.
  45. Loi S, Adams S, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086. Ann Oncol. 2017;28(Suppl.5):v605-v649. https://doi.org/10.1093/annonc/mdx440
  46. Yuan Y, Frankel P, Synold T. A phase II clinical trial of the combination of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor positive triple negative breast cancer. ). In: Poster presented at: 2017 San Antonio Breast Cancer Symposium (SABCS). December 7, 2017; San Antonio, TX. Publ number: OT1-05-02.
  47. Schmid P, Cruz C, Braiteh F.S. Patients with triple-negative breast cancer who responded to atezolizumab had long-term survival benefit. In: Presented at: 2017 American Association for Cancer Research (AACR): Annual Meeting. 4/4/2017. abstr.2986.
  48. Kok M, Horlings HM, van de Vijver K, Wiersma T, Russell N, Voorwerk, et al. LBA14 Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial. Ann Oncol. 2017;28(Suppl.5):mdx440.006. https://doi.org/10.1093/annonc/mdx440.006
  49. Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Hamilton EP, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase IB Javelin Solid Tumor Trial. Breast Cancer Res Treat. 2018;67(3):671-686. https://doi.org/10.1007/s10549-017-4537-5
  50. Gibson J. Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol. 2015;16(6):e264. https://doi.org/10.1016/S1470-2045(15)70208-1
  51. De Iuliis F, Salerno G, Taglieri L, Scarpa S. Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review. Cancer Chemother Pharmacol. 2015;76(4):679-690. https://doi.org/10.1007/s00280-015-2818-4
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.